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Abstract  
Background Atrial fibrillation (AF) relapses, following transcatheter AF ablation, are frequently 
reported based on patients’ symptoms, scheduled electrocardiograms (ECGs) or 24-h Holter 
recordings. The aim of the present study is to determine the incidence of asymptomatic and 
symptomatic AF recurrences, using continuous subcutaneous ECG monitoring, in the long-term 
follow-up of patients with paroxysmal or persistent AF undergoing transcatheter ablation. 
Methods and Results One hundred and thirteen consecutive patients symptomatic for paroxysmal 
or persistent AF were enrolled. All patients underwent pulmonary vein isolation plus left linear 
lesions. The Insertable Cardiac Monitor (ICM), subcutaneously implanted during the ablation 
procedure, recorded the amount of AF per day (Daily Burden) and per last follow-up period (total 
AF Burden). Based on symptoms and on scheduled 12-lead ECG performed during follow-up 40 
patients (35.4%) suffered AF recurrences. By means of ICM data, however, arrhythmia relapses 
were recorded within 75 patients (66.3%) of whom 35 (46.7%) were asymptomatic. Patients 
suffering symptomatic AF recurrences resulted, at univariate analysis, older (66.6±8.4 vs. 61.6±10.7 
years) and suffering greater AF burden (88.8±26.9 vs. 8.0±8.0%).  
Conclusions AF ablation outcome based on patients’ symptoms and/or scheduled ECGs 
underestimated relapses, as up to half of the patients, during a long-term follow-up, suffer 
asymptomatic recurrences.  
 
 
Key-words: paroxysmal and persistent atrial fibrillation, asymptomatic recurrences, transcatheter 
ablation 
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Introduction 
Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with substantial 
morbidity, primarily related to symptoms, and thromboembolic events (1). Radiofrequency catheter 
ablation (RCA) has been proposed as an alternative treatment for highly symptomatic drug-
refractory paroxysmal and persistent AF.  
Following AF ablation anticoagulant and antiarrhythmic therapy, not free from side effects, are to 
date mainly prescribed based on the patients’ symptoms, routine electrocardiograms (ECGs) or 24-h 
Holter recordings. For this reason, asymptomatic, paroxysmal recurrences of AF may remain 
undetected (2-6) basing the decision to terminate or continue such therapies on unreliable data.  
Insertable cardiac monitors (ICMs) requiring a minimally invasive procedure have instead proven 
highly sensitive in detecting AF and accurate in measuring the duration of AF in terms of daily 
burden. (7). 
The aim of the present study is to determine the incidence of asymptomatic and symptomatic AF 
recurrences, by ICM, in the long-term follow-up of patients with paroxysmal or persistent AF 
undergoing transcatheter ablation. 
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Methods 
Patient population 
Paroxysmal atrial fibrillation (PAF) was defined according to the latest ESC guidelines (8) as one or 
more episodes self-terminating, within 48 hours. Although paroxysmal AF may continue for up to 7 
days. Persistent AF was defined as an AF episode either lasting longer than 7 days or requiring 
termination by cardioversion, either with drugs or by direct current cardioversion (DCC).  
Inclusion criteria for the present study were: 1) symptomatic drug-refractory AF (at least two anti-
arrhythmic drugs attempted); 2) paroxysmal AF with documented monthly episodes; or 3) 
persistent AF in patients who had already undergone three or more electrical cardioversions. 
Exclusion criteria were: previous AF ablation procedure or patients who refused device 
implantation. 
Out of the 123 consecutive patients undergoing transcatheter ablation of AF between January 2007 
to December 2011 at the Civic Hospital of Ciriè, Turin (Italy) and meeting the inclusion criteria, 
113 (91.9%) were willing to implant an implantable cardiac monitor and provided written informed 
consent.  
 
Study protocol  
Pre-operative care. A detailed clinical examination, thyroid function tests, ECG, chest radiography, 
Holter monitoring, and transthoracic and transesophageal echocardiography were routinely 
performed. All patients were treated with oral anticoagulation using warfarin sodium to achieve an 
international normalized ratio of 2 to 3 for three weeks before catheter ablation. 
Mapping and ablation procedure. CT scans of thorax were performed before the procedure. The left 
atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real time 
three dimensional (3D) LA maps were reconstructed by using a no fluoroscopic navigation systems 
(Carto, Biosense Webster, or Nav-X, St. Jude Medical). Each PVs was encircled. The endpoint of 
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circumferential PV isolation was confirmed when Lasso mapping showed the disappearance of all 
PV potentials or the dissociation of PV potentials from left atrial activity. All patients were treated 
with PV isolation. Linear lesions were performed with left isthmus and roof line in patients with 
persistent AF. The cavotricuspid isthmus was ablated in case of concomitant demonstration of 
common atrial typical flutter.  
The device implant. The ICM (Reveal XT, Medtronic, Minneapolis, Minnesota) was implanted 
during the same ablation procedure. ICM continuously classifies the heart rhythm of the patient by 
analyzing the beat-to-beat variability of cardiac cycles on a 2-minute ECG strip. The device records 
the amount of AF per day (Daily Burden, hours in AF in one day) and the AF Burden of the follow-
up (FU) period, defined as the percentage of time in AF (AF%). The trend in daily AF burden, 
together with all AF-related parameters, are shown by the programmer on FU examination through 
the Cardiac Compass® Reports, a specific software that summarizes the data stored during the FU 
period. The ICM was implanted in the parasternal area of the chest. The technical requirement for 
guiding the final position was an R-wave amplitude >0.4 mV assessed by Vector Check. 
ICM was programmed as proposed in the XPECT Trial (9) and all ICM data was independently 
reviewed by two physicians blinded to patient symptoms; conflict was resolved by common 
agreement referring to a third expert. 
In brief, AF detection algorithm uses irregularity and incoherence of R-R intervals. The R-R 
intervals are analyzed within each 2-minute period of time, and the difference in duration between 
consecutive R-R intervals is calculated. Subsequently, the variability of these intervals is calculated, 
similar to constructing a Lorenz plot. When the R-R intervals within the 2-minute interval show a 
certain pattern of uncorrelated irregularity the heart rhythm in this interval is classified as AF. 
Based on this algorithm sensitivity, specificity, positive predictive value, and negative predictive 
value for identifying patients with any AF are 96%, 85%, 79%, and 97%, respectively with an 
overall accuracy of the ICM for detecting AF of above 98%.  
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Post-operative care. Following ablation, cardiac rhythm was monitored by telemetry for at least 4 h 
and 12-lead ECG was performed at 12, 24, 36h and 3-6-12 months or in case of symptoms, namely, 
palpitations, dizziness or dyspnea (if similar to that suffered pre-ablation). In case of symptoms the 
patients was recorded as “symptomatic” independently from eventual corroboration or not with a 
rhythm strip. All patients received the Carelink remote monitoring service (Medtronic, Minneapolis, 
Minnesota) for home monitoring. The transmission of ICM data was performed monthly in an 
established day or in case of symptoms.  
The ICMs data and symptom diaries were collected at each visit. The telemetric data and the ECG 
stored were used to tailor the antiarrhytmic and oral anticoagulant therapy. In case of symptoms 
patient was suggested to perform a transmission of ICM or an ECG in order to confirm/exclude AF 
recurrence. 
Oral anticoagulation was reinstituted the day after ablation and heparin infusion was continued until 
international normalized ratio levels exceeded 2.  All patients were treated with warfarin for at least 
3 to 6 months after ablation and then it was discontinued in patients without recurrence of atrial 
fibrillation and CHADs Vasc ≤1 and with no other indications for anticoagulation. In case of 
recurrent AF, warfarin was reintroduced. In the absence of arrhythmia recurrence during this initial 
surveillance period, antiarrhytmic drugs were not prescribed. In the event of early AF recurrence, 
patients with or without of structural heart disease received Amiodarone, Sotalol or Flecainide.  
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Statistical Analysis 
Univariate comparisons of categorical variables (presented as counts and percentages) were 
performed in crosstabulation tables by means of the Pearson chi-square test and of continuous 
variables (expressed as the mean value ± SD) by the two-tailed Student t test for unpaired data. 
Value of p ≤ 0.05 was considered statistically significant. All analysis were performed using SPSS 
(version 20 SPSS Inc, Chicago, IL, USA). 
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Results 
One hundred and thirteen consecutive patients (64.3±10.3 years, 78 males) were enrolled. Baseline 
characteristics are depicted in Table 1. Patients were followed for 1222, 6±4364.9 days after the 
ablation procedure. None of them were lost at follow-up. 
The duration of transcatheter ablation procedure and ICM implantation was on average 183±64.1 
min, fluoroscopic time was 26.3±8.8 min and the radiofrequency application per patient was 
56.4±16.2 min. We had 4 inguinal hematomas and 1 atrio-ventricular fistula, none requiring 
treatments. There was 1 pericardial effusion which did not require pericardiocentesis. No 
complications regarding ICM implantation. 
Based on symptoms and on 12-lead ECG performed at follow-up 40 patients (35.4%) had 
symptomatic AF recurrences. At univariate analysis these patients were older (66.6±8.4 vs. 
62.3±10.9 years; p 0.027), more hypertensive (85.0 vs. 57.5; p=0.039) and presented greater ICM 
AF burden (88.8±26.9 vs. 4.5±3.5%; p < 0.01; (Table 2).  
By means of ICM  - intra-observer variability between the two physicians reading ICM records was 
6% - 75 patients (66.3%) documented an atrial arrhythmia recurrence, asymptomatic in 35 cases 
(46.7%; Figure 1).  
Baseline characteristics, medical therapy at discharge, procedural and follow-up data of patients 
stratified by symptomatic or asymptomatic atrial fibrillation recurrences are reported in Table 3. At 
univariate analysis more advanced age (66.6±8.4 vs. 61.6±10.7 years; p 0.029)  and a greater AF 
burden (88.8±26.9 vs. 8.0±8.0%; p<0.001; Figure 2) related to symptoms during AF recurrences.  
Ventricular rate during AF relapses, in addition, was higher in symptomatic (100 ± 3.2 bpm) vs. 
asymptomatic (vs. 80±4.6 bpm, p< 0.001) patients.  
  
10
Based on ICM findings 6 (5.3%) patients continued oral anticoagulants due to asymptomatic AF 
despite a CHADS-Vasc score <1 and 35 (30.9%) discontinued oral anticoagulants due to absence of 
AF despite a CHADS-Vasc score ≥1. 
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Discussion 
Long-term continuous monitoring detects more atrial arrhythmia recurrences following AF 
transcathter ablation compared to patient referred symptoms or intermittent ECG monitoring (7). In 
our study two out of three patients suffered an AF relapse over a median follow-up of about two 
years.  
Weerasooriya et al. have previously followed 100 patients with paroxysmal or persistent AF 
undergoing transcatheter ablation finding that arrhythmia free survival rates were 87%, 81% and 
63% at 1,2 and 5 years, respectively (10). On the other hand, Ouyang et al. found that after a 
median follow-up of 4.8 years, stable sinus rhythm was achieved in 79.5% of the patients with 
symptomatic paroxysmal AF undergoing circumferential pulmonary vein isolation (11). A previous 
experience of our group, instead, documented that 53% of the patients with paroxysmal AF was in 
sinus rhythm at 3-year follow-up (vs. 57% at 12-months follow-up), while 41% of the patients with 
persistent AF was in sinus rhythm at 3-year follow-up (vs. 45% at 12-months follow-up) (12). 
Although the wide variation of relapses reported in the already mentioned long-term experiences, 
most probably due to the high heterogeneity of patients and arrhythmia durations (paroxysmal vs. 
persistent) involved, the percentage of relapses detected by continuous rhythm monitoring is indeed 
higher. In fact, the silent form of AF may otherwise be noticed only incidentally through pre-
planned physical examinations, office electrocardiography, preoperative assessments, or population 
surveys. In some cases, asymptomatic AF is revealed only after complications such as stroke or 
congestive heart failure have occurred (13). In the present population, over a median follow-up 
about of 2 years, about half of the patients suffering a relapse were asymptomatic. In search of 
asymptomatic relapses Pontoppidan et al. followed 149 patients after pulmonary vein ablation by 7-
day Holter monitoring and found that 44% of the patients had asymptomatic arrhythmia recurrences 
at 12 months (14). Moreover Hindricks G et al. found that even in patients presenting with highly 
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symptomatic AF, asymptomatic episodes may occur and significantly increase after catheter 
ablation (5 vs.37%) (15). In lack, to date, of proven pre or post ablation predictors of asymptomatic 
recurrences of AF the present dataset, although based on univariate analysis only, proposes age and 
AF as parameters potentially related to asymptomatic AF recurrences. The latter, confirming the 
recent report from Verma et al. showing that the post ablation state was the strongest independent 
predictor of asymptomatic AF recurrences and that asymptomatic patients suffered shorter episodes 
(16).  
Clinical implications. Assessment of clinical results of transcatheter AF ablation by long-term 
follow-up is crucial given the high percentage of recurrences reported already after the first year. 
Great caution must be taken before judging AF “suppressed” or “cured”; in fact there is a high 
prevalence of asymptomatic recurrences. Continuous AF monitoring provides an optimal picture of 
both symptomatic and asymptomatic daily AF burden and a better assessment of therapy. 
Study limitations. This is a single-center study with a limited simple size. For this reason, although 
correlations were not significant at univariate analysis at discharge, a multivariate approach 
investigating whether drug treatment at follow-up (e.g. antiarrhythmic or ß-blockers) may blunt 
patient perception of arrhythmia remains unresolved. Second, symptoms considered within 
“symptomatic” patients might not necessarily be related to AF (17). The plausible over estimation 
of symptoms would, however, not artificially emphasize study results but, in case, limit the gap 
within “conventional” and ICM-based follow-up. Third, our population was primarily composed of 
patients with persistent AF treated in more than 90% of the cases by additional linear lines on top of 
PV isolation. Given the poor sensitivity and specificity of the ICM algorithms used to detect AF on 
regular atrial tachyarrhythmias, their incidence may result underestimated.  
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Conclusion 
Transcatheter AF ablation outcome should not be based on symptoms or pre-planned ECG follow-
up, as half of the patients with recurrences are asymptomatic during a long-term follow-up. The 
management of oral anticoagulation therapy and anthiarrhytmic drugs should therefore be based on 
more reliable data increasing knowledge on this arrhythmia and offering the possibility of tailored 
therapy. 
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Figure 1. Atrial fibrillation recurrences over the long-term follow-up based on symptoms and 
follow-up 12-lead ECGs and ICM data. 
 
 
Figure 2. AF burden (%) over the long-term follow-up based on Insertable Cardiac Monitor data in 
patients reporting asymptomatic and symptomatic atrial fibrillation recurrences.  
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TABLE 1 
Baseline characteristics of the Patient Population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Defined as prior peripheral artery disease or presence of aortic plaque. SD= standard deviation; LVEF= left ventricular 
ejection fraction; PVI=pulmonary vein isolation ; CTI= cavotricuspidal  isolation; AF= atrial fibrillation. TIA= transient 
ischemic attack. 
 
Variables 
 
All 
N=113 
Age, years ( SD) 64.3±10.3 
Male, n (%) 78 (69) 
Type of atrial fibrillation, n (%)  
Paroxysmal 10 (8.8) 
Persistent 103 (91.2) 
Risk factors for thromboembolism, n (%)  
Cardiac failure 2 (1.8) 
Hypertension 76 (67.2) 
Diabetes mellitus 15 (13.3) 
Prior stroke/TIA 6 (5.3) 
Vascular disease* 7 (6.5) 
LVEF, % (SD) 57.9±5.3 
Medical therapy at discharge, n (%)  
Beta blockades  71 (62.8) 
Digitalis  6 (5.3) 
Calcium channel blockers 3 (2.7) 
Antiarrhythmic drugs  42 (37.2) 
Anticoagulants 113 (100) 
Antiplatelet agents 9 (8) 
Type of ablation, n(%)  
PVI  
PVI plus linear lesions 
10 (8.8) 
103 (91.2) 
CTI 18 (15.9) 
Follow up (±SD)  
Duration of follow up, days 1222.6±4364.9 
Mean AF burden, % of time 35.1±30.6 
Max AF duration, hours 18.7±17.6 
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TABLE 2 
Baseline characteristics of the Patient Population based on symptoms and follow-up by 12-lead ECGs. 
 
 
Variables 
 
No 
recurrences 
N=73 
Recurrences 
 
N=40 
P value 
Age, years (±SD) 62.3±10.9 66.6±8.4 0.027 
Male, n (%) 55 (75.3) 23 (57.5) 0.335 
Type of atrial fibrillation, n (%)    
Paroxysmal 9 (12.3) 1 (2.5) 0.078 
Persistent 64 (87.7) 39 (97.5) 0.078 
Risk factors for thromboembolism, n (%)    
Cardiac failure 1 (1.4) 1 (2.5) 0.730 
Hypertension 42 (57.5) 34 (85.0) 0.039 
Diabetes mellitus 10 (13.7) 5 (12.5) 0.797 
Prior stroke/TIA 3 (4.1) 3 (7.5) 0.541 
Vascular disease* 2 (2.7) 5 (12.5) 0.061 
LVEF, % (SD) 57.8±5.2 58.5±5.1 0.495 
Medical therapy at discharge, n (%)    
Beta blockades  47 (64.4) 24 (60) 0.156 
Digitalis  2 (2.7) 4 (10) 0.095 
Calcium channel blockers 1 (1.4) 2 (5) 0.243 
Antiarrhythmic drugs  27 (37.0) 15 (37.5) 0.067 
Anticoagulants 73 (100) 40 (100) - 
Antiplatelet agents 6 (8.2) 3 (7.5) 0.018 
Type of ablation, n (%)    
PVI  
PVI plus linear lesion 
9 (12.3) 
64 (87.7) 
1 (2.5) 
39 (97.5) 
0.157 
0.157 
CTI 16 (21.9) 2 (5.0) 0.143 
Follow up (±SD)    
Duration of follow up, days 713.8±264.5 788.2±288.2 0.027 
Mean AF burden, % of time 4.5±3.5 88.8±26.9 <0.001 
Max AF duration, hours 16.5±16.5 26.2±21.7 0.265 
 
*Defined as prior peripheral artery disease or presence of aortic plaque. AF=atrial fibrillation; SD= Standard deviation; 
LVEF=  Left ventricular ejection fraction; PVI= Pulmonary vein isolation; CTI= cavotricuspidal isolation; TIA= 
transient ischemic attack 
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Table 3 
Characteristics of Patient Population based on ICM data. 
Variables 
 
Asymptomatic 
patients 
N=35 
Symptomatic 
patients 
N=40 
P value 
Age, years (SD) 61.6±10.7 66.6±8.4 0.029 
Male, n (%) 27 (77.1) 23 (57.5) 0.262 
Type of atrial fibrillation, n (%)    
Paroxysmal 4 (11.4) 1 (2.5) 0.088 
Persistent 31 (88.6) 39 (97.5) 0.088 
Risk factors for thromboembolism, n (%)    
Cardiac failure 0 (0) 1 (2.5) 0.347 
Hypertension 24 (68.6) 34 (85) 0.133 
Diabetes mellitus 3 (8.6) 5 (12.5) 0.612 
Prior stroke/TIA 1 (2.8) 3 (7.5) 0.374 
Vascular disease* 1 (2.8) 5 (12.5) 0.125 
LVEF, % (SD) 58.4±4.2 58.5±5.1 0.918 
Medical therapy at discharge, n (%)    
Beta blockades  19 (54.3) 24 (60) 0.249 
Digitalis  1 (2.8) 4 (10) 0.185 
Calcium channel blockers 1 (2.8) 2 (5) 0.223 
Antiarrhythmic drugs  12 (34.3) 15 (37.5) 0.084 
Anticoagulants 35 (100) 40 (100) - 
Antiplatelet agents 3 (8.6) 3 (7.5) 0.029 
Type of ablation, n (%)    
PVI  
PVI plus linear lesion 
4 (11.4) 
31 (88.6) 
1 (2.5) 
39 (97.5) 
0.279 
0.279 
CTI 10 (28.6) 3 (7.5) 0.036 
Follow up (±SD)    
Duration of follow up, days 669.6±288.9 788.2±282.2 0.137 
Mean AF burden, % of time 8.0±8.0 88.8±26.9 <0.001 
Max AF duration, hours 18.9±18 26.2±21.7 0.402 
 
*Defined as prior peripheral artery disease or presence of aortic plaque. AF=atrial fibrillation; SD= Standard deviation; 
LVEF=  Left ventricular ejection fraction; PVI= Pulmonary vein isolation; CTI= cavotricuspidal isolation; TIA= 
transient ischemic attack 
 
